RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
NCT06155136 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 163
Last updated 2024-04-22
Summary
The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI
Conditions
- Pancreatic Cancer Metastatic
Sponsors & Collaborators
-
Servier Affaires Médicales
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-06
- Primary Completion
- 2024-03-30
- Completion
- 2024-09-30
Countries
- Germany
Study Locations
More Related Trials
-
A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China
NCT07026123 ·Status: NOT_YET_RECRUITING
-
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer: An Analysis Using NHIS Database and K-PaC Registry Focusing on Liposomal Irinotecan
NCT04984174 ·Status: COMPLETED
-
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
NCT02468557 ·Status: TERMINATED ·Phase: PHASE1
-
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
NCT06700603 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
NALIRIFOX as Induction Therapy in LAPC
NCT06467565 ·Status: RECRUITING ·Phase: PHASE2
-
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
NCT03883919 ·Status: COMPLETED ·Phase: PHASE1
-
Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
NCT06006728 ·Status: COMPLETED
-
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
NCT06571461 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235 ·Status: COMPLETED ·Phase: PHASE3
-
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
NCT06172036 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Irinotecan Liposome in Combination With Capecitabine
NCT06578052 ·Status: RECRUITING ·Phase: NA
-
Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
NCT05095064 ·Status: UNKNOWN
-
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
NCT03693677 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
NCT05074589 ·Status: COMPLETED ·Phase: PHASE3
-
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
NCT06662006 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
NCT05047991 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473 ·Status: RECRUITING
-
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
NCT05511116 ·Status: UNKNOWN
-
Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma
NCT06485739 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
NCT05181605 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
NCT01505530 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
NCT04796948 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Ruxolitinib in Pancreatic Cancer Patients
NCT01423604 ·Status: COMPLETED ·Phase: PHASE2
-
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
NCT03496662 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Sirolimus in Patients With Advanced Pancreatic Cancer
NCT03662412 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2